

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

### **Notice Concerning Receipt of Statement of Intent for the Large-scale Purchase Actions etc. Pertaining to the Large-scale Purchase etc. of Company Share Certificates etc.**

**TOKYO, August 18, 2025** - ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) (the “Company”) hereby gives notice that on August 18, 2025, the Company received from Dalton Investments, Inc. (“Dalton”), Nippon Active Value Fund PLC (“NAVF”), and NAVF Select LLC (“NAVF Select”; Dalton, NAVF, and NAVF Select are referred to collectively as “Dalton etc.”) a “Statement of Intent for Large-scale Purchase Actions etc.” pertaining to the Large-scale Purchase etc. of Company share certificates etc. (“Statement of Intent”).

According to the Statement of Intent, (i) while Dalton etc. intend to purchase Company shares up to a maximum of shares representing about 30% of total voting rights (total number of issued shares *minus* treasury shares), they may, depending on circumstances, acquire less than approximately 30% of the total voting rights or dispose of their shares; (ii) it is planned that the acquisition of Company shares by Dalton etc. will in principle be carried out in market trading; (iii) with purchase funds primarily sourced from assets managed under discretionary investment agreements, sufficient financial capacity is in place (iv) there is a possibility that going forward, Dalton etc. will make proposals to the Company as shareholders that they believe will contribute to enhancement of corporate value and to the common interests of shareholders (including capital policy, compensation plans, dissolution of share cross-holdings, and composition of board of directors); and (v) that if the decision is made to delist the Company, Dalton etc. intend to provide support, including the introduction of an independent financial advisor.

In response to this, the Company’s board of directors, in accordance with the “Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purchase etc. of Company Share Certificates etc. by Dalton etc.” introduced by the Company on July 1, 2025 (“Response Policy”), plans to deliver to Dalton etc., within five business days excluding August 18, 2025, an information list, with the purpose of requesting the provision of information necessary for the Company’s board of directors and shareholders to consider the terms of the Large-scale Purchase etc.

We ask our shareholders to be on the lookout for disclosures from the Company going forward.

For details of the Response Policy, please see the timely disclosure materials below .

- Company press release dated July 1, 2025, “Notice Concerning Introduction of Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purchase etc. of Company Share Certificates etc. by Dalton etc.” The above timely disclosure materials can be seen at the following URL on the Company website.

URL: <https://ssl4.eir-parts.net/doc/4886/tdnet/2649902/00.pdf>

End

---

**Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)